Pathologic changes associated with androgen deprivation therapy for prostate cancer.

Area of Science:

• Oncology
• Pathology
• Urology

Background:

• Androgen deprivation therapy (ADT) is a cornerstone in managing advanced prostate cancer.
• Leuprolide and flutamide are commonly used agents for ADT, inducing significant hormonal changes.
• Understanding treatment-related histologic changes is crucial for accurate pathologic assessment.

Purpose of the Study:

• To evaluate pathologic changes in prostate glands following ADT with leuprolide +/- flutamide.
• To correlate histologic alterations with treatment and initial tumor characteristics.
• To assess the impact of ADT on prostate cancer cell morphology.

Main Methods:

• Light microscopic examination of pre- and post-treatment prostate tissue.
• Visual discrimination and quantitative measurements of neoplastic gland size and distribution.
• Histologic assessment correlated with tumor grade, clinical stage, and prostate-specific antigen expression.

Main Results:

• Treatment-related alterations in neoplastic gland size and distribution observed in 60% of cases via visual inspection.
• Quantitative measurements revealed glandular changes in a higher percentage of cases.
• Histologic patterns were not specific to leuprolide/flutamide; absence of significant necrosis suggests suppression rather than ablation.

Conclusions:

• ADT with leuprolide/flutamide induces distinct but non-specific histologic changes in prostate cancer.
• The observed effects suggest a suppressive rather than ablative mechanism of action.
• Accurate histologic assessment is achievable with thorough examination and awareness of drug-induced morphologic variations.